---
title: Antibiotic-induced loss of gut microbiome metabolic output correlates with
  clinical responses to CAR T-cell therapy
date: '2024-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39441941/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241023205824&v=2.18.0.post9+e462414
source: Blood
description: Antibiotic-induced microbiome dysbiosis is widespread in oncology, adversely
  affecting outcomes and side effects of various cancer treatments, including immune
  checkpoint inhibitors and chimeric antigen receptor T (CAR-T) cell therapies. In
  this study, we observed that prior exposure to broad-spectrum ABX with extended
  anaerobic coverage like piperacillin-tazobactam and meropenem was associated with
  worsened anti-CD19 CAR-T therapy survival outcomes in large B-cell lymphoma patients
  ...
disable_comments: true
---
Antibiotic-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T (CAR-T) cell therapies. In this study, we observed that prior exposure to broad-spectrum ABX with extended anaerobic coverage like piperacillin-tazobactam and meropenem was associated with worsened anti-CD19 CAR-T therapy survival outcomes in large B-cell lymphoma patients ...